

DECHRA¹

OPHTHALMIC²

OINTMENTS³

ARE BACK⁴

Now you can treat your canine and feline patients with the trusted ophthalmic products, **VETROPOLYCIN[®]** (bacitracin-neomycin-polymyxin) Veterinary Ophthalmic Ointment and **VETROPOLYCIN[®] HC** (bacitracin-neomycin-polymyxin-hydrocortisone acetate 1%) Veterinary Ophthalmic Ointment, that are FDA-CVM approved for use in dogs and cats. The choice is clear. Contact your Dechra Representative or your Veterinary Distributor for more information.



24 Hour Technical Support available from trained Veterinary Professionals. | 866-933-2472

As with all drugs, side effects may occur. In field studies, the most common side effects reported were ocular itching, burning, or inflammation in animals sensitive to the product. Prolonged use may result in the overgrowth of non-susceptible organisms including fungi. **VETROPOLYCIN ONLY**— Do not use as a pre-surgical ocular lubricant. **VETROPOLYCIN HC ONLY**— This product is not for use in animals with corneal ulcers, fungal infections, or viral infections. Patients should be monitored for signs of corticosteroid overdose. The safe use of this product has not been evaluated in pregnant animals. Refer to the prescribing information for VETROPOLYCIN and VETROPOLYCIN HC for complete details or visit www.dechra-us.com.



Dechra
Veterinary Products

VETROPOLYCIN®

bacitracin-neomycin-polymyxin
veterinary ophthalmic ointment

STERILE - ANTIBACTERIAL

NADA # 065-016. Approved by FDA.

DESCRIPTION: Each gram contains Bacitracin Zinc 400 units, Neomycin Sulfate 5 mg (equivalent to 3.5 mg of Neomycin base), Polymyxin B Sulfate 10,000 units in a base of White Petrolatum and Mineral Oil.

ACTIONS: The three antibiotics present in Vetropolycin® (bacitracin-neomycin-polymyxin) veterinary ophthalmic ointment provide a broad spectrum of activity against the gram-positive and gram-negative bacteria commonly involved in superficial infections of the eyelid and conjunctiva. Bacitracin is effective against gram-positive bacteria including hemolytic and non-hemolytic streptococci and staphylococci. Resistant strains rarely develop. Neomycin is effective against both gram-positive and gram-negative bacteria including staphylococci, Escherichia coli and Haemophilus influenzae and many strains of Proteus and Pseudomonas. Polymyxin B is bactericidal to gram-negative bacteria especially Pseudomonas. No resistant strains have been found to develop in vivo.

INDICATIONS: In the treatment of superficial bacterial infections of the eyelid and conjunctiva in dogs and cats when due to organisms susceptible to the antibiotics contained in the ointment. Laboratory tests should be conducted including in vitro culturing and susceptibility tests on samples collected prior to treatment.

PRECAUTIONS: Sensitivity to Vetropolycin® (bacitracin-neomycin-polymyxin) veterinary ophthalmic ointment is rare; however, if a reaction occurs, discontinue use of the preparation. As with any antibiotic preparation, prolonged use may result in the overgrowth of non-susceptible organisms including fungi. Appropriate measures should be taken if this occurs. If infection does not respond to treatment in two or three days, the diagnosis and therapy should be re-evaluated. Care should be taken not to contaminate the applicator tip of the tube during the application of the preparation. Do not allow the applicator tip to come in contact with any tissue.

ADVERSE REACTIONS: Itching, burning or inflammation may occur in animals sensitive to the product. Discontinue use in such cases. For a copy of the Material Safety Data Sheet (MSDS), or to report adverse reactions, call Dechra Veterinary Products at (866) 933-2472.

DOSAGE AND ADMINISTRATION: Apply a thin film over the cornea three to four times daily in dogs and cats. The area should be properly cleansed prior to the use of the Vetropolycin® (bacitracin-neomycin-polymyxin) veterinary ophthalmic ointment. Foreign bodies, crusted exudates, and debris should be carefully removed.

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

WARNING: Do not use this product as a pre-surgical ocular lubricant. Adverse reactions of ocular irritation and corneal ulceration have been reported in association with such use. Serious hypersensitivity (anaphylactic) reactions have been reported in cats within 4 hours of application of antibiotic ophthalmic preparations. Some of these reactions have resulted in death.

HOW SUPPLIED: 3.5 g (1/8 Oz) sterile tamper proof tubes.

NDC 17033-028-38.

STORE AT 15°-25°C (59°-77°F).

Manufactured for:
Dechra Veterinary Products,
Overland Park, KS 66211

033495-00-I Ini0912 R0514



VETROPOLYCIN® HC

bacitracin-neomycin-polymyxin-
hydrocortisone acetate 1%
veterinary ophthalmic ointment

STERILE - ANTIBACTERIAL

NADA # 065-015. Approved by FDA.

DESCRIPTION: Each gram contains Bacitracin Zinc 400 units, Neomycin Sulfate 5 mg (equivalent to 3.5 mg of Neomycin base), Polymyxin B Sulfate 10,000 units, Hydrocortisone Acetate 10 mg (1%), in a base of White Petrolatum and Mineral Oil.

ACTIONS: The overlapping spectra of these three antibiotics provide effective bactericidal action against most commonly occurring gram-positive and gram-negative bacteria associated with infections of the eyes. The range of bactericidal activity encompasses many bacteria which are, or have become, resistant to other antibiotics, notably Pseudomonas and Staphylococcus. In susceptible organisms, resistance rarely develops, even on repeated or prolonged usage. Hydrocortisone acetate exerts a marked anti-inflammatory action at the tissue level and effectively suppresses inflammation in many disorders of the anterior segment of the eye. Local application to the eye often gives rapid relief of pain and photophobia, particularly in lesions of the cornea. The combined anti-inflammatory and antimicrobial activity of Vetropolycin® HC (bacitracin-neomycin-polymyxin-hydrocortisone acetate 1%) veterinary ophthalmic ointment permits effective management of many disorders of the anterior segment of the eye in which combined activity is needed.

INDICATIONS: It may be used in acute or chronic conjunctivitis, when caused by organisms susceptible to the antibiotics contained in this ointment. Laboratory tests should be conducted including in vitro culturing and susceptibility tests on samples collected prior to treatment.

CONTRAINDICATIONS: Ophthalmic preparations containing corticosteroids are contraindicated in the treatment of those deep, ulcerative lesions of the cornea where the inner layer (endothelium) is involved, in fungal infections and in the presence of viral infections.

WARNINGS: All topical ophthalmic preparations containing corticosteroids with or without an antimicrobial agent, are contraindicated in the initial treatment of corneal ulcers. They should not be used until the infection is under control and corneal regeneration is well under way. Serious hypersensitivity (anaphylactic) reactions have been reported in cats within 4 hours of application of antibiotic ophthalmic preparations. Some of these reactions have resulted in death. Clinical and experimental data have demonstrated that corticosteroids administered orally or by injection to animals may induce the first stage of parturition if used during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Additionally, corticosteroids administered to dogs, rabbits, and rodents during pregnancy have resulted in cleft palate in offspring. Corticosteroids administered to dogs during pregnancy have also resulted in other congenital anomalies, including deformed forelegs, phocomelia, and anasarca.

PRECAUTIONS: Sensitivity to this ophthalmic ointment is rare, however, if a reaction occurs, discontinue use of the preparation. The prolonged use of antibiotic-containing preparations may result in overgrowth of non-susceptible organisms including fungi. Appropriate measures should be taken if this occurs. If infection does not respond to treatment in two or three days, the diagnosis and therapy should be re-evaluated. Animals under treatment with this product should be observed for usual signs of corticosteroid overdose which include polydipsia, polyuria and occasionally an increase in weight. Use of corticosteroids, depending on dose, duration, and specific steroid, may result in inhibition of endogenous steroid production following drug withdrawal. In patients presently receiving or recently withdrawn from systemic corticosteroid treatments, therapy with a rapidly acting corticosteroid should be considered in unusually stressful situations. Care should be taken not to contaminate the applicator tip during the administration of the preparation.

ADVERSE REACTIONS: Itching, burning or inflammation may occur in animals sensitive to the product. Discontinue use in such cases. SAP and SGPT (ALT) enzyme elevations, polydipsia and polyuria have occurred following parenteral or systemic use of synthetic corticosteroids in dogs. Vomiting and diarrhea (occasionally bloody) have been observed in dogs. Cushing's syndrome in dogs has been reported in association with prolonged or repeated steroid therapy. For a copy of the Material Safety Data Sheet (MSDS), or to report adverse reactions, call Dechra Veterinary Products at (866) 933-2472.

DOSAGE AND ADMINISTRATION: Apply a thin film over the cornea three or four times daily. The area to be treated should be properly cleansed prior to use. Foreign bodies, crusted exudates and debris should be carefully removed. Insert the tip of the tube beneath the lower lid and express a small quantity of the ointment into the conjunctival sac in dogs and cats.

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

HOW SUPPLIED: 3.5 g (1/8 Oz) sterile tamper proof tubes.

NDC 17033-030-38.

STORE AT 15°-25°C (59°-77°F).

Manufactured for:
Dechra Veterinary Products, Overland Park, KS 66211
033496-00-I Ini0912 R0514



Dechra
Veterinary Products